Mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
| Property | Value | Notes |
|---|---|---|
| Typical storage | Minus 20 C or below | Lyophilized powder, protected from light |
| Solubility class | Freely soluble in water | Also dissolves in normal saline |
| Identity method | Mass spectrometry | Measured mass compared with calculated value |
| Purity method | Reverse-phase HPLC | Reported as area percentage of main peak |
| Common counterion | Acetate | Salt form varies by supplier and batch |
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
An ideal drug delivery system should have effective targeting and controlled release. The two main targeting strategies are passive targeting and active targeting. Passive targeting depends on the fact that tumors have abnormally structured blood vessels that favor accumulation of relatively large macromolecules and nanoparticles. This so-called enhanced permeability and retention effect (EPR) allows the drug-carrier be transported specifically to the tumor cells. Active targeting is, as the name suggests, much more specific and is achieved by taking advantage of receptor-ligand interactions at the surface of the cell membrane. Controlled drug release systems can be achieved through several methods. Rate-programmed drug delivery systems are tuned to the diffusivity of active agents across the membrane. Another delivery-release mechanism is activation-modulated drug delivery, where the release is triggered by environmental stimuli. The stimuli can be external, such as the introduction of a chemical activators or activation by light or electromagnetic fields, or biological - such as pH, temperature, and osmotic pressure which can vary widely throughout the body.
== Regulation == Speculation on the power of systems that have been called "molecular assemblers" has sparked a wider political discussion on the implication of nanotechnology. This is in part due to the fact that nanotechnology is a very broad term and could include "molecular assemblers". Discussion of the possible implications of fantastic molecular assemblers has prompted calls for regulation of current and future nanotechnology. There are very real concerns with the potential health and ecological impact of nanotechnology that is being integrated in manufactured products. Greenpeace for instance commissioned a report concerning nanotechnology in which they express concern into the toxicity of nanomaterials that have been introduced in the environment. However, it makes only passing references to "assembler" technology. The UK Royal Society and Royal Academy of Engineering also commissioned a report entitled "Nanoscience and nanotechnologies: opportunities and uncertainties" regarding the larger social and ecological implications of nanotechnology. This report does not discuss the threat posed by potential so-called "molecular assemblers".
The parathyroid and thyroid glands in the neck produce those hormones; thus, problems with those glands (such as hypo- or hyperparathyroidism or hypo- or hyperthyroidism) can create problems with bone mineral density (as well as hypo- or hypercalcaemia).
CoviVac – COVID vaccine Cytestrol acetate – antiestrogen, cytostatic antineoplastic agent Deltaran (delta sleep-inducing peptide) – alcohol withdrawal treatment Dilept (GZR-123) – antipsychotic, neurotensin analogue Diucifon – leprostatic agent Emoxypine (Mexidol; Mexifin) – actoprotector, antioxidant EpiVacCorona – COVID vaccine Eprobemide (Befol) – antidepressant, reversible inhibitor of monoamine oxidase A Ethacizine (ethacyzine; Ethacizin) – antiarrhythmic agent Fabomotizole (Afobazole) – anxiolytic Feprosidnine (Sydnophen) – amphetamine derivative, psychostimulant Fluacizine (Phtorazisin) – tricyclic antidepressant, phenothiazine Fluorothiazinone (CL-55; Ftortiazinon) – investigational antibiotic Fotretamine (Fotrin) – alkylating antineoplastic agent, immunosuppressant Gamofen (gamophen; amphetamine–GABA) – amphetamine derivative, GABATooltip γ-aminobutyric acid analogue, central agent, central depressant Gidazepam (hydazepam, hidazepam) – atypical benzodiazepine, anxiolytic, TSPOTooltip translocator protein agonist/ligand Gludantan (gludantane) – adamantane, antiparkinsonian agent, antidepressant Glufimet (RGPU-238; dimethyl 3-phenylglutamate) – GABATooltip γ-aminobutyric acid and phenibut analogue Glutaron (RGPU-135; neuroglutamine, neuroglutam; β-phenylglutamate; 3-phenylglutamate) – glutamate analogue, psychostimulant, antidepressant, anxiolytic, neuroprotective Hemantane (hymantane) – adamantane, antiparkinsonian agent Hopantenic acid (homopantothenic acid; N-pantoyl-GABA; Pantogam) – central depressant, GABATooltip γ-aminobutyric acid analogue Ipidacrine (Neiromidin) – acetylcholinesterase inhibitor Latrepirdine (dimebolin; Dimebon) – antihistamine, antiserotonergic, nootropic Mecigestone (pentarane B) – progestin Megestrol caproate (MGC) – progestin Meldonium (Mildronate) – anti-ischemia agent Menthyl isovalerate (validolum; Extravalerianic, Validol, Valofin, Menthoval) – anxiolytic Mesocarb (Sidnocarb, Sydnocarb, Synocarb) – amphetamine derivative, psychostimulant Methylphenatine – amphetamine derivative, psychostimulant Methylphenylpiracetam – racetam, sigma σ1 receptor positive allosteric modulator α-Methyltryptamine (αMT; Indopan) – tryptamine derivative, antidepressant Metralindole (Inkazan) – antidepressant, reversible inhibitor of monoamine oxidase A Moracizine (moricizine; Ethmozine) – antiarrhythmic agent Nooglutyl (Nooglutil; N-5-hydroxynicotinoyl-L-glutamate) – nootropic Orenetide (BP101; Libicore; Desirix; Thr-Lys-Pro-Arg-Pro) – investigational small peptide, sexual enhancer Pabofen (pabophen; amphetamine–PABA) – amphetamine derivative, antihypoxic agent Pentarane A (D'6-pentarane) – progestin Phemerazole (femerazol; 5-phenyl-3-methylpyrazole) – sedative, hypnotic, anticonvulsant, muscle relaxant, mammary stimulant Phenatine (phenatin; Fenatine; amphetamine–niacin; N-nicotinoylamphetamine) – amphetamine derivative, psychostimulant, hypotensive agent Phenazepam – benzodiazepine, anxiolytic, sedative, hypnotic Phenibut (β-phenyl-GABA; Anvifen, Fenibut, Noofen; Citrocard, RGPU-147) – central depressant, anxiolytic, GABATooltip γ-aminobutyric acid analogue, gabapentinoid N-Phenylacetyl-L-prolylglycine ethyl ester (omberacetam; Noopept) – nootropic, racetam, cyclic glycine-proline prodrug Phenylphenamine (phenylamphetamine) – amphetamine derivative Phenylpiracetam (fonturacetam; Phenotropil, Actitropil, Carphedon) – psychostimulant, nootropic, racetam Phenylpiracetam hydrazide (fonturacetam hydrazide) – anticonvulsant, racetam Picamilon (N-nicotinoyl-GABA, pycamilon, and pikamilon) – anxiolytic, GABATooltip γ-aminobutyric acid analogue Pipofezine (Azafen, Azaphen) – tricyclic antidepressant Pirlindole (Lifril, Pyrazidol) – antidepressant, reversible inhibitor of monoamine oxidase A, serotonin–norepinephrine reuptake inhibitor Polymethylsiloxane polyhydrate (PMSPH; methylsilicic acid hydrogel; Enterosgel) – enterosorbent Propylphenamine (propylamphetamine; possibly N-propylamphetamine) – amphetamine derivative Prospidium chloride (prospidine) – cytostatic, anti-inflammatory agent Pyridoxiphen (amphetamine–pyridoxine; pyridoxylamphetamine) – amphetamine derivative, sympatholytic, hypotensive agent Quifenadine (Phencarol, Fencarol) – antihistamine RGPU-95 (p-chlorophenylpiracetam) – antidepressant, anxiolytic, racetam RGPU-207 (cyclic GABA derivative) – GABATooltip γ-aminobutyric acid analogue, mitochondrial modulator, racetam RGPU-260 – GABATooltip γ-aminobutyric acid analogue, cardiac stimulant Riamilovir (Triazavirin) – antiviral RU-1205 – analgesic, kappa opioid receptor agonist Selank – tuftsin analogue, nootropic, anxiolytic Semax – ACTHTooltip adrenocorticotropic hormone fragment analogue, nootropic, neuroprotective, neurorestorative Sodium polydihydroxyphenylene thiosulfonate (Hypoxen) – antihypoxic agent Sputnik Light – COVID vaccine Sputnik V – COVID vaccine Sulfozinum (sulfazin) – pyrogenic and pain-inducing agent used in psychiatry, for instance psychosis Temgicoluril (tetramethylglycoluril; Adaptol, Mebicar, Mebicarum, Mebikar) – anxiolytic Testifenon (testiphenon, testiphenone, chlorphenacyl dihydrotestosterone ester) – androgen/anabolic steroid, cytostatic antineoplastic agent Tetrindole – antidepressant, reversible inhibitor of monoamine oxidase A Thiophenatine (N-thionicotinoylamphetamine) – amphetamine derivative Tipindole – serotonin antagonist and monoamine oxidase inhibitor Tolibut (β-(4-methylphenyl)-GABA)) – anxiolytic, analgesic, neuroprotective, GABATooltip γ-aminobutyric acid and phenibut analogue Traneurocin (cycloprolylglycine; CPG; NA-831) – racetam-like neuroprotective, neurogenic, nootropic, and anxiolytic Trimeperidine – opioid analgesic Umifenovir (Arbidol) – antiviral Vishnevsky liniment – topical wound medication Phenamine (Fenamin), a psychostimulant, is not specifically a Russian drug but is rather the Russian name for amphetamine.
Rezafungin, sold under the brand name Rezzayo (by Melinta Therapeutics), is a medication used for the treatment of invasive candidiasis. It is an echinocandin antifungal that acts as a fungal β-glucan synthase inhibitor. Rezafungin was approved for medical use in the United States in March 2023, and in the European Union in December 2023.
Sources: en.wikipedia.org
There are other applications of this method where the PdII complexes were generated as PdII-peptide OACs by introducing 4-halophenylalanine into peptides during SPPS to achieve peptide-peptide or peptide-protein ligation.
=== Concept === Many airports had terminals too small for "aerobuses". In the West, the solution to this involved constructing greater airport capacity. By contrast, Soviet aviation research institutes addressed ways of increasing passenger throughput without the need for additional airport capacity. Many Soviet airports also had surfaces too weak for "aerobuses". The Soviet solution again favoured adapting aircraft to existing conditions, rather than reconstructing airports. The aerobus thus had to match the ground loadings of existing airliners. This called for complex multi-wheel landing gear. The Soviet solution to the airport capacity issue involved passengers loading and unloading their own luggage into and from the aircraft. This was eventually called "the luggage at hand system" (Russian: "система «багаж с собой»"; transliterated: "sistyema bagazh s soboy"). Soviet aviation journalist Kim Bakshmi described it (at its ultimate) thus: "One arrives five minutes prior to departure, buys oneself a ticket on board the aircraft, hangs one's coat next to the seat and places one's bag or suitcase nearby." Taking suitcases into the cabin, as in trains, was studied, but necessitated a 3 m fuselage extension with a 350-seat capacity. To avoid this, passengers were to deposit their luggage in underfloor compartments as they entered the airliner. Ideas similar to the "luggage at hand system" were briefly addressed in the West. Airbus studied such an arrangement in the mid-1970s.
== References == This article was adapted from the following source under a CC BY 4.0 license (2021) (reviewer reports): Yingxuan Ma; Kim Johnson (2021). "Arabinogalactan-proteins" (PDF). WikiJournal of Science. 4 (1): 2. doi:10.15347/wjs/2021.002. Wikidata Q99557488.
Per- and Polyfluoroalkyl Substances (PFAS) at the National Toxicology Program Per- and Polyfluoroalkyl Substances and Your Health at the Agency for Toxic Substances and Disease Registry Per- and Polyfluoroalkyl Substances (PFAS) at the EPA Per- and polyfluoroalkyl substances (PFASs) at the European Chemicals Agency PFAS contamination map of Europe Per- and Polyfluoroalkyl substances, National Institute for Occupational Safety and Health The Forever Pollution Project – Journalists tracking PFAS across Europe PFAS contamination in Queensland, Australia, State Library of Queensland "Contaminated: The Carpet Industry's Toxic Legacy". Frontline. Season 44. Episode 8. 3 February 2026. PBS. WGBH. Retrieved 25 February 2026.
Sources: en.wikipedia.org
== Further reading == Morris, S., Otto, N. C., Golemboski, K. (2013). Improving patient safety and healthcare quality in the 21st century—Competencies required of future medical laboratory science practitioners. Clinical Laboratory Science, 26, 200–204. Archibong, F., Atangwho, A., Ayuk, E. A., Okoye, E. I., Atroger, M., Okokon, B. I. (2019). Medical law: exploring doctor's knowledge on the laws regulating clinical and medical laboratories in Nigeria. Nigerian Journal of Medicine, 28(4), 386–392. Plebani, M., Laposata, M., Lippi, G. (2019). Driving the route of laboratory medicine: a manifesto for the future. Internal and Emergency Medicine, 14, 337–340. Goulding, M. H., Graham, L., Chorney, D., Rajendram, R. (2020). The use of interprofessional stimulation to improve collaboration and problem solving among undergraduate BHSc medical laboratory science and BScN nursing students. Canadian Journal of Medical Laboratory Science, 82(2), 25–33.
Furthermore, prices for Fmoc amino acids were high until the large-scale piloting of one of the first synthesized peptide drugs, enfuvirtide, began in the 1990s, when market demand adjusted the relative prices of Fmoc- vs Boc- amino acids.
=== Tyrannosaurus imperator and Tyrannosaurus regina === In a 2022 study, Gregory S. Paul and colleagues argued that Tyrannosaurus rex, as traditionally understood, actually represents three species: the type species Tyrannosaurus rex, and two previously unrecognized species: T. imperator (meaning "tyrant lizard emperor") and T. regina (meaning "tyrant lizard queen"). The holotype of the former (T. imperator) is the Sue specimen, and the holotype of the latter (T. regina) is Wankel rex. The division into multiple species was primarily based on the high degree of variation in the proportions and robusticity of the femur (and other skeletal elements) across T. rex specimens. Presumed robust and gracile morphotypes and the number of small incisiform teeth in the dentary were also used as a line of evidence. Paul and colleagues categorized the species as follows: T. rex demonstrates robust anatomy, a moderate ratio of femur length vs circumference, and the possession of a singular slender incisiform dentary tooth, T. imperator is robust with a small femur length to circumference ratio and two of the slender teeth, and T. regina is more gracile with a high femur ratio and one of the slender teeth. However, several leading paleontologists, including Stephen Brusatte, Thomas Carr, Thomas Holtz, David Hone, Jingmai O'Connor, and Lindsay Zanno, criticized the study or expressed skepticism of its conclusions.
== External links == How wounds heal and tumors form With this simple Flash demonstration, Harvard professor Donald Ingber explains how wounds heal, why scars form, and how tumors develop. Presented by Children's Hospital Boston. Wound Healing and Repair Lorenz H.P. and Longaker M.T. Wounds: Biology, Pathology, and Management. Stanford University Medical Center. Romo T. and McLaughlin L.A. 2003. Wound Healing, Skin. Emedicine.com. Rosenberg L. and de la Torre J. 2003. Wound Healing, Growth Factors. Emedicine.com. After the Injury- Children's Hospital Of Philadelphia
Initially, there was a misconception that due to its predominantly water-based composition, cartilage had a Poisson's ratio of 0.5 and should be modeled as an incompressible material. However, subsequent research has disproven this belief. The Poisson's ratio of articular cartilage has been measured to be around 0.4 or lower in humans and ranges from 0.46–0.5 in bovine subjects. The mechanical properties of articular cartilage are largely anisotropic, test-dependent, and can be age-dependent. These properties also depend on collagen-proteoglycan interactions and therefore can increase/decrease depending on the total content of water, collagen, glycoproteins, etc. For example, increased glucosaminoglycan content leads to an increase in compressive stiffness, and increased water content leads to a lower aggregate modulus.
Sources: en.wikipedia.org
The standard approach is reverse-phase high-performance liquid chromatography, reported as a percentage of total peak area. Because that figure alone says little about the nature of the impurities, the accompanying chromatogram is normally the more useful document for judging a batch.
Cold storage at minus twenty degrees Celsius or below is the common recommendation for the lyophilized powder, together with protection from light and moisture. Dissolved material is generally treated as less stable and is handled cold with short working windows.
A useful certificate lists the analytical method used, the measured purity, the mass determined by spectrometry, and the storage conditions. Independent verification from a second laboratory is sometimes requested, since supplier-issued documents are not always produced in the same facility as the material.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.